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Respiratory failure in the acute respiratory syndrome coronavirus
2 (SARS-CoV-2) pandemic is hypothesized to be driven by an over-
reacting innate immune response, where the complement system
is a key player. In this prospective cohort study of 39 hospitalized
coronavirus disease COVID-19 patients, we describe systemic com-
plement activation and its association with development of respira-
tory failure. Clinical data and biological samples were obtained at
admission, days 3 to 5, and days 7 to 10. Respiratory failure was
defined as PO2/FiO2 ratio of ≤40 kPa. Complement activation prod-
ucts covering the classical/lectin (C4d), alternative (C3bBbP) and com-
mon pathway (C3bc, C5a, and sC5b-9), the lectin pathway recognition
molecule MBL, and antibody serology were analyzed by enzyme-
immunoassays; viral load by PCR. Controls comprised healthy blood
donors. Consistently increased systemic complement activation was
observed in themajority of COVID-19 patients during hospital stay. At
admission, sC5b-9 and C4d were significantly higher in patients with
than without respiratory failure (P = 0.008 and P = 0.034). Logistic
regression showed increasing odds of respiratory failure with sC5b-9
(odds ratio 31.9, 95% CI 1.4 to 746, P = 0.03) and need for oxygen
therapy with C4d (11.7, 1.1 to 130, P = 0.045). Admission sC5b-9 and
C4d correlated significantly to ferritin (r= 0.64, P< 0.001; r= 0.69, P<
0.001). C4d, sC5b-9, and C5a correlated with antiviral antibodies, but
not with viral load. Systemic complement activation is associatedwith
respiratory failure in COVID-19 patients and provides a rationale for
investigating complement inhibitors in future clinical trials.
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The ongoing pandemic with the novel severe acute respiratorysyndrome coronavirus 2 (SARS-CoV-2) can lead to life-
threatening pneumonia and multiple organ failure, termed
COVID-19 (1). SARS-CoV-2 infection triggers activation of the
innate immune system. It has been hypothesized that a dysregu-
lated innate immune response promotes a phenotype of respira-
tory failure that may lead to acute respiratory distress syndrome
(ARDS) and marked cytokine release (2, 3). Respiratory failure is
the main reason for hospital admission and mortality in COVID-
19 patients, and new therapeutic interventions are desperately
needed (3).
The complement system is a key player in the innate immune
response and acts as a danger-sensing alarm system, relying on
soluble pattern recognition molecules (4). Complement is acti-
vated through three different pathways. The classical pathway is
triggered by antibodies, but also by acute phase proteins like
C-reactive protein (CRP). Lectin pathway recognition molecules
are mannose-binding lectin (MBL), several ficolins, and collec-
tins. The main function of the alternative pathway is to amplify
the initial activation from the classical and lectin pathway
through the central C3 component, which, in turn, activates C5.
Activation of C5 then leads to formation of the potent
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anaphylatoxin C5a and the terminal C5b-9 complement complex,
both exerting proinflammatory actions like recruitment of neu-
trophils, activation of the adaptive immune system, and endo-
thelial cell activation. By cross-talk with other defense systems like
the toll-like receptors and the hemostatic system, the complement
system contributes substantially to protection against invading mi-
crobes. However, whereas the complement system is important in
tissue homeostasis and immune surveillance, overwhelming com-
plement activation may contribute to destructive inflammation
harming the host (5, 6).
Complement activation has previously been associated with
respiratory failure, ARDS development, and severity in bacterial
and viral pneumonia (7, 8). The coronaviruses SARS and Middle
East Respiratory Syndrome have both been described to potently
induce complement activation, which, in turn, contributes to the
development of respiratory failure (9, 10). One preliminary study
investigating sC5b-9 and C5a taken within the first week in 31
patients admitted to a critical care unit has shown higher levels in
those in need of invasive respiratory therapy (11). Case reports in
COVID-19 patients have revealed evidence for deposition of ac-
tivated complement proteins in lung and other organ tissues (12) in
colocalization with COVID-19 spike glycoproteins, hence partici-
pating in microvascular injury and thrombosis (13). Indeed, ex-
perimental evidence suggests that coronavirus N protein:MASP-2
interaction leads to an uncontrolled activation of the complement
lectin pathway (14), and, recently, complement was postulated as a
target for therapy in COVID-19 patients (15).
Moreover, the well-established complement inhibitor eculizu-
mab that prevents cleavage of C5, and a neutralizing antibody to
C5a, have shown beneficial effect in patient subgroups with
COVID-19 (14, 16) in line with one paper showing increased
levels of C5a in COVID-19 patients at admission (17). One case
was recently treated with the C3 inhibitor compstatin (AMY-101)
(18). So far, data on increased systemic complement activation on
a broad level of activation products in COVID-19 patients are
lacking, and such data will be a prerequisite for complement in-
hibition as a successful therapeutic approach.
Thus, this study aims to identify the degree and time point of
systemic complement activation in COVID-19 patients using a
broad spectrum of complement activation products, relate
complement activation to clinical course with particular focus on
the development of respiratory failure, and thus give a basis for
designing clinical trials of therapeutic complement inhibition in
COVID-19 patients.
Results
Thirty-nine SARS-CoV-2−positive patients were included in the
study (Fig. 1). Healthy blood donors served as reference pop-
ulation, with an upper reference limit set at the 95th percentile.
Respiratory failure, defined according to the ARDS Berlin def-
inition as PO2/FiO2 ratio of ≤40 kPa regardless of mechanical
ventilatory support, was prominent at admission or developed
during hospital stay in 23 patients (59%; Table 1), graded to
mild, moderate, and severe in 11, 9, and 3 patients, respectively.
Baseline characteristics revealed significant differences in myal-
gia, fatigue, PO2/FiO2 ratio, need for oxygen therapy, and Se-
quential Organ Failure Assessment (SOFA) score between
patients with and without respiratory failure (Table 1). Respi-
ratory failure patients showed significantly increased signs of
inflammation (white blood cell count and ferritin) and signifi-
cantly higher fibrin degradation parameter d-dimer at admission
(Table 1).
Complement Activation in Relation to the Degree of Respiratory Failure.
Throughout hospital stay, complement activation markers were
above upper reference limit for 74% of assessed samples for sC5b-9,
59% for C5a, 97% for C3bc, 67% for C3bBbP, and 77% for C4d,
indicative of long-lasting activation of the complement system (SI
Appendix, Fig. S1 A–E). All five complement activation products
significantly correlated with each other, suggesting consistent acti-
vation of the whole complement system (SI Appendix, Fig. S2 A–E).
Patients with respiratory failure at admission showed signifi-
cantly higher levels of sC5b-9 and C4d, but not of C5a, C3bc, and
C3bBbP, compared to patients with no respiratory failure
(Fig. 2 A–E). The same pattern was observed when including
patients who developed respiratory failure during hospital stay,
that is, sC5b-9 and C4d were significantly higher at admission in
these patients than in patients never experiencing respiratory
failure (P = 0.03 and P = 0.02, respectively). In the mixed model
analysis, which included all time points, a significant main effect
of daily respiratory failure status on sC5b-9 (F = 5.08, P = 0.03)
and C4d (F = 5.34, P = 0.03) was found, and this effect was
dependent on the difference at admission, while it was, at all
time points, absent on the other complement activation markers.
Likewise, a significant main effect of need for oxygen therapy
was found on C4d only (F = 14.24, P = 0.001), also dependent on
the differences at admission.
Complement Activation in Relation to the Different Markers of
Respiratory Failure. Regression analysis revealed significant asso-
ciation of sC5b-9 with PO2/FiO2 ratio (Table 2). Increased sC5b-9
at admission increased odds for daily assessed respiratory failure
significantly (OR 31.9 [CI 1.3 to 746.6], P = 0.03). Increased C4d
at admission significantly increased odds for need for oxygen
therapy (11.7 [1.1 to 130.4], P = 0.045). Increased sC5b-9 at ad-
mission favored increase of respiratory failure severity stage
according to ARDS definition in an ordinal regression analysis by
Fig. 1. Enrollment and follow-up of patients with COVID-19. Flowchart of
inclusion of patients with positive COVID-19 status into the cohort study.
Blood sampling to biobank, along with progression of blood data available
at each successive time point. Logistic difficulties means that, although pa-
tient was available and had consented, no blood was collected at this
time point.










































20% (P = 0.03). None of the other complement activation prod-
ucts or the recognition molecule MBL were significantly associ-
ated with any outcome variables characterizing respiratory failure
(Dataset S1).
Complement Activation in Relation to Markers of Systemic Inflammation,
Hemostasis, and Renal Function. Clinical laboratory markers of in-
flammation ferritin, CRP, and white blood cell count were signifi-
cantly correlated with sC5b-9 at admission (r = 0.64, P < 0.001; r =
0.51, P = 0.006; r = 0.38, P = 0.047, respectively). Ferritin at ad-
mission was, in addition, significantly correlated with C4d (r = 0.69,
P < 0.001) and C3bc (r = 0.53, P = 0.005). Platelet count and
d-dimer were not significantly correlated with any complement ac-
tivation product. At admission, sC5b-9, C4d, and C3bc significantly
explained 28% (P = 0.005), 26% (P = 0.007), and 24% (P = 0.01) of
the variation of ferritin, while only sC5b-9 in addition explained
17% of CRP (P = 0.03) in a linear regression analysis (Dataset S1).
During the whole time course, only ferritin and CRP were signifi-
cantly correlated with sC5b-9 and C4d, and CRP correlated also
with MBL (SI Appendix, Fig. S2F). Parameters of renal function,
estimated glomerular filtration rate (eGFR) and creatinine, were
not correlated with complement activation products either at ad-
mission or over the whole time course, except for C3bc and eGFR,
which showed a weak, significant association (r = 0.25, P = 0.03).
Complement Activation in Relation to Antibodies against SARS-CoV-2.
IgG and IgM against the receptor binding domain (RBD) of the
Spike protein were detectable at admission in 60% and 70% of
all patients, respectively, and, over time, in 100% and 95% of
patients, respectively (SI Appendix, Fig. S3). IgG and IgM against
the nucleocapsid protein of the CoV were detectable at admis-
sion in 70% and 17% of all patients, respectively, and, over time,
in 100% and 40% of patients, respectively (SI Appendix, Fig. S3).
Evidence of a relationship between detectable antibodies against
SARS-CoV-2 and complement activation products above upper
reference limit was significant for IgG RBD and IgG nucleo-
capsid protein compared to C4d only (χ2 4.80 and 6.92, P = 0.03
and P = 0.009, respectively; SI Appendix, Table S1). Correlation
of absolute antibody and complement activation product levels
were significant for IgG nucleocapsid protein and C4d (r = 0.30,
P = 0.01) and IgM nucleocapsid protein with sC5b-9, C4d, and
C5a only (r = 0.27, 0.32, 0.24; P = 0.02, 0.006, 0.03, respectively;
SI Appendix, Table S2). Antinucleocapsid IgG and IgM levels
together with sC5b-9 levels at admission were associated with
respiratory failure at admission (OR 37.7 [CI 1.3 to 1,081.9], P =
0.03 and 33.8 [1.6 to 689.5], P = 0.02, respectively). Anti-
nucleocapsid IgM together with sC5b-9 at admission were as-
sociated with respiratory failure during the whole hospital stay
(14.4 [1.1 to 184.8], P = 0.03) (Dataset S1).
Table 1. Demographics, clinical characteristics, and laboratory and radiology findings at admission day
Total (n = 39) Non-respiratory failure (n = 16) Respiratory failure (n = 23) P value
Demographics and clinical characteristics
Age (years) 61 (49 to 74) 63 (49 to 75) 59 (50 to 70) 0.7
Sex 0.3
Female 10 (25) 6 (38) 4 (17)
Male 29 (75) 10 (62) 19 (83)
Comorbidity
Hypertension 7 (18) 4 (25) 3 (13) 0.3
Diabetes 4 (10) 2 (13) 2 (9) 0.7
Chronic cardiac disease 9 (23) 4 (25) 5 (22) 0.8
Chronic lung disease 9 (23) 5 (31) 4 (17) 0.3
Cancer 2 (5) 2 (13) 0 0.06
Chronic kidney disease 4 (10) 2 (13) 2 (9) 0.7
Symptoms before admission
Fever (temperature ≥ 37.3 °C) 34 (87) 15 (94) 19 (83) 0.5
Cough 32 (82) 14 (88) 18 (79) 0.5
Sputum 12 (31) 3 (19) 9 (38) 0.2
Sore throat 11 (28) 5 (31) 6 (26) 0.3
Myalgia 21 (54) 11 (69) 10 (44) 0.04
Fatigue 30 (77) 11 (69) 19 (83) 0.03
Diarrhea 8 (21) 3 (19) 5 (22) 0.3
Nausea or vomiting 15 (39) 6 (38) 9 (39) 0.3
Shortness of breath 23 (59) 7 (44) 16 (70) 0.1
Symptoms and scores at admission
Need for oxygen therapy 30 (77) 9 (56) 21 (91) 0.02
PO2/FiO2 ratio 39 (30 to 45) 47 (45 to 58) 32 (22 to 39) <0.01
qSOFA score 1 (0 to 1) 0 (0 to 1) 1 (0 to 1) 0.07
SOFA score 2 (1 to 3) 1 (0.5 to 2) 2 (2 to 3) 0.03
NEWS score 4.0 (1.8 to 7.0) 3 (1.3 to 5.8) 6 (3.5 to 8) 0.3
Time from first symptom to hospital admission, days 8 (6 to 11) 8 (5 to 11) 9 (7 to 12) 0.6
Laboratory findings
White blood cell count, x109/L 5.6 (4.8 to 7.7) 4.9 (4.1 to 5.7) 6.6 (5.3 to 9.7) <0.01
Platelet count, x109/L 191 (155 to 231) 180 (150 to 204) 198 (166 to 233) 0.2
D-dimer, mg/L 0.8 (0.6 to 2.0) 0.6 (0.4 to 1.0) 1.0 (0.8 to 2.5) 0.04
Ferritin, μg/L 796 (363 to 1355) 498 (267 to 773) 1112 (691 to 1476) 0.01
CRP, mg/L 67 (31 to 146) 50 (25 to 76) 114 (44 to 153) 0.05
Data are median (25th to 75th percentile) or n (percent). P values were calculated using Mann−Whitney U test, χ2 test, or Fisher’s exact test, as appropriate.
P < 0.05 highlighted bold and italic. Respiratory failure is defined as PO2/FiO2 ratio <40 kPa.






















Complement Activation in Relation to Viral Load. Samples to corre-
late viral load with complement activation at admission were
available for 21 patients. Viral load ranged from 3.4 to 8.7 (log10
viral RNA copies per mL) with a median of 5.3 (interquartile range
3.8 to 7.3). No significant correlation between viral load and com-
plement activation products was found (SI Appendix, Table S3).
Notably, viral load at admission was not associated with develop-
ment of respiratory failure, nor with respiratory failure during the
whole hospital stay (Dataset S1).
MBL Levels in the COVID-19 Cohort. MBL, the main recognition
molecule of the lectin pathway, was very similar to the established
levels of MBL in the normal population (Fig. 2F and SI Appendix,
Fig. S2F), with a modest increase at days 3 to 5, consistent with an
acute phase reaction. Only one patient showed MBL levels below
100 ng/mL at all three time points, consistent with hereditary MBL
defect, and this patient did not experience respiratory failure.
An Example of Extreme In Vivo Complement Activation. One patient
in whom the first and only sample was obtained 7 d after end of
the inclusion period and thus 17 d after admission to the hos-
pital, while no clinical data were registered at this time point, was
not included in the material and statistics. This patient displayed
an extremely high degree of complement activation reflected by
all products (see Materials and Methods for type of units; here
given as the level in this patient [upper reference range and
percent increase compared to this in parentheses]): sC5b-9 = 12
(<0.7; 1,714%); C5a = 18 (<2; 900%); C3bc = 80 (<9; 889%);
C3bBbP = 94 (<29; 329%); and C4d = 2,536 (<1,000; 253%). At
this time point, viral load was in the 25% quartile of the study




Fig. 2. Complement activation products (A−E) and MBL (F) levels in COVID-19 patients with and without respiratory failure at admission and days 3 to 5,
and days 7 to 10 of hospitalization. COVID-19 patients were divided according to presence of respiratory failure at day of sampling (defined as PO2/FiO2
ratio ≤40 kPa). At admission, patients with respiratory failure had significantly higher levels of sC5b-9 (A) and C4d (E) compared to patients without re-
spiratory failure. The majority of patients had all assessed complement activation products well above the upper reference limits, represented by the dotted
lines, at every time point and for every activation product. Results are presented as box plots (line, median; box, interquartile range) with whiskers (10th to
90th percentile). For MBL, the values above the upper dotted line (>500 ng/mL) represent normal values, those between the dotted lines represent low values
(100 ng/mL to 500 ng/mL), and those below the lower dotted line represent MBL defects (<100 ng/mL). Mann−Whitney U test. URL, upper reference limit;
CAU, complement arbitrary units.










































against RBD and nucleocapsid protein present, while IgM were
negative. This patient died several days later in a state of mul-
tiple organ failure including respiratory failure.
Discussion
In the present study, a majority of COVID-19 patients showed a
consistent increased activation of the complement system, with
values above the upper reference limit at hospital admission and
throughout the following 10 d. The terminal complement com-
plex sC5b-9 plasma levels were significantly increased in patients
with respiratory failure at admission compared to those without
respiratory failure. Further, sC5b-9 was associated with daily re-
spiratory failure status.
COVID-19 patients develop virus-related pneumonia, which
may lead to life-threatening respiratory failure. The pathophysi-
ology is not fully understood, but SARS-CoV-2 will bind to and
cause inflammation in vascular endothelium in general. Increasing
evidence suggests that respiratory failure develops due to intra-
alveolar endothelial damage, resulting in destructive inflammatory
responses and terminal complement sC5b-9 deposition in prox-
imity to microvascular injury and thrombosis (13, 19). Increased
systemic sC5b-9 and C5a levels have been described in patients
admitted to intensive care, while here we show that systemic
complement activation is present in the majority of COVID-19
patients admitted to hospital and, importantly, this activation was
associated with the presence of respiratory failure at admission or
evolvement during hospitalization (11).
Standard clinical parameters of inflammation were correlated
with the terminal complement activation product sC5b-9,
underscoring the crosstalk between the complement system and
other parts on the inflammatory cascade during severe COVID-
19 disease (5, 20). A case-series reported antiphospholipid an-
tibodies associated coagulopathy in COVID-19 patients, a state
known to induce complement activation that is possible to treat
with complement inhibition (21, 22). Thus, complement inhibi-
tion was recently suggested as a treatment option for thrombosis
in COVID-19 patients (23). The similarity in the pathophysiol-
ogy of COVID-19 and endotheliopathies like atypical hemolytic
uremic syndrome (aHUS) was recently reviewed (24). The fact
that these conditions, in particular aHUS, are efficiently treated
with a complement inhibitor, has increased the interest for
complement therapy in COVID-19 disease.
The long-lasting activation of the complement system with the
majority of patients showing levels above clinically accepted ref-
erence ranges for days to weeks after hospital admission as ob-
served in this study is of importance. Complement activation
products are short-lived and degrade within seconds, like C5a, to 1
h, like sC5b-9. They rapidly return to baseline levels after a single
and short-lived stimulus, like extracorporeal circulation or acute
trauma (25). Notably, our findings support a state of persistent
complement activation in hospitalized COVID-19 patients, which
is in-line with findings of increased sC5b-9 and C5a levels in pa-
tients admitted to intensive care unit (11). The significance of this
prolonged complement activation is uncertain, but one can spec-
ulate that it may be caused by antibody production, a continuous
viral load with subsequent endothelial, and tissue damage with
release of alarmins keeping the complement system activated and
inflammation prolonged (1).
We found weak correlations between antibodies and comple-
ment activation products in this cohort. Anti-virus IgG displayed
a relationship to C4d, only. The classical complement pathway is
immediately activated after recognition of danger molecules and
is not completely antibody dependent. Only if antibodies are
already present after a previous infection or vaccination, anti-
body binding will initiate classical pathway activation immedi-
ately. Thus, while we find some evidence of relationship between
anti-virus IgGs and the classical pathway, classical pathway ac-
tivation could also be due to direct C1 activation since acute
phase proteins like CRP can activate C1 directly (26). C4d is
generated from the lectin pathway, too, and the lectin pathway is
directly activated as first line defense by collectins, ficolins, and
MBL, independent of antibodies (27). Thus, we found that an-
tibodies may play a role in the activation of complement in
COVID-19 patients. However, this relationship does not seem to
be crucial in maintaining the complement response. Hence, an-
tibodies against COVID-19 might represent a double-edged
sword; beneficial by neutralizing the virus and detrimental by
contributing to over-activation of the complement system as
described previously in SARS-CoV infection (28).
SARS-CoV-2 viral load has recently been associated with
plasma levels of interferons and cytokines (29). Here, we show
that the innate immune response by the complement system at
hospital admission is not correlated with viral load. However,
hospital admission occurred at a median of 8 d after first disease
symptoms, and we therefore cannot exclude that the initial viral
load might be associated with complement system activation.
The complement system is part of the first-line host defense; that
is, it acts upstream and induces a secondary inflammatory re-
sponse including cytokine production, recruitment of leukocytes,
and involvement of the adaptive immune system (4). Therefore,
different patterns of association with viral load are explainable
and add to the complex picture of immune system activation by
SARS-CoV-2.
Likewise, inhibition of the complement system early in the
course of an aggravated COVID-19 disease seems reasonable and
might be feasible by attenuating the overactivation of the in-
flammatory system. We suggest that this may be a more powerful
strategy than targeting single downstream molecules, like cyto-
kines IL-6 or tumor necrosis factor, which are synthesized later in
the course after the immediate immune recognition and activation
have occurred (30).
Table 2. Associations between complement and respiratory failure characteristics in COVID-19
patients at hospital admission: Results from linear, logistic, and ordinal regression
Type of model/covariates R2 or OR 95% CI df or n P value
Linear regression
sC5b-9 vs. PO2/FiO2 ratio 0.160 R
2 [−19.12 to −1.154] 29 df 0.028
Logistic regression
sC5b-9 vs. daily RF 31.905 OR [1.363 to 746.632] 30 n 0.031
C4d vs. need for oxygen therapy 11.714 OR [1.052 to 130.421] 27 n 0.045
Ordinal regression
sC5b-9 vs. daily RF stage* 0.201 R2 [0.132 to 3.047] 30 n 0.033
RF, respiratory failure (defined as PaO2/FiO2 ratio ≤40 kPa) registered daily. OR, odds ratio. dF, degrees of
freedom. Nagelkerke`s adjusted pseudo R2 was used to estimate the coefficient in ordinal regression analyses.
*RF stage according to ARDS Berlin definition (none, mild, moderate, severe).






















Which specific complement proteins, activation products, or
complement receptors should be inhibited is debatable, as in-
hibitors for many complement targets exist (31). This study re-
ports broad activation of the whole complement system, including
C4d from the classical and/or lectin pathway, and C3bBbP from
the alternative pathway; thus, specific inactivation of one of the
initial pathways seems less likely to result in beneficial clinical
effects. As discussed above, whether C4 activation originated from
the classical, lectin, or both pathways cannot be concluded from
our data.
We measured MBL from the lectin pathway, because it is a
very frequent deficiency in the normal population of which 10 to
30% have low levels (32); however, it should be emphasized that
the concentration of MBL does not indicate whether the lectin
pathway is activated or not. In addition, it has been documented
that MBL deficiency increases the risk of SARS-CoV infection
(33). In our cohort, MBL levels were comparable to the normal
population and even slightly fewer deficiencies were observed
than expected (32). Thus, COVID-19 patients have an operative
recognition through the lectin pathway, which might be a pre-
requisite for the described complex formation of the virus’ N
protein with MASP-2, one of the serine proteases in the lectin
pathway. The anaphylatoxins C3a and C5a and the terminal
complement complex C5b-9 are the most potent inducers of
inflammation, and inhibition of these should thus be prioritized.
Thus, therapeutic inhibition on the level of the common pathway
including C3 or C5 inhibition seems most promising in light of
the results from this study.
The results in this study are obtained from a small patient
cohort, restricting analyses of eventual association between
complement activation and survival, as well as generalization of
our findings to other cohorts. However, age, sex, and comor-
bidity distributions are comparable to larger observational co-
hort studies using the same database registry (34). Thus, these
results should be regarded as a hypothesis-generating study for
enabling power and sample size estimation for highly desired
future clinical studies.
In conclusion, here we show that the complement system is ac-
tivated systemically in the majority of COVID-19 patients admitted
to hospital. All complement activation products were increased, but,
especially, the terminal complement sC5b-9 was associated with
respiratory failure and systemic inflammation. A hallmark in this
patient population is a prolonged and substantial complement sys-
tem activation. Thus, randomized controlled clinical trials of com-
plement inhibition in COVID-19 patients are justified.
Materials and Methods
Study Design and Participants.
Patients. This prospective observational study included two cohorts of adult
hospitalized patients (≥18 y old) not included in any randomized clinical trial
from Oslo University Hospital and Drammen Hospital, Vestre Viken Hospital
Trust, Norway. Informed consent was obtained from all patients’ next-of-kin
if the patient was incapacitated to give consent. The SARS-CoV-2 study
aiming at virological, clinical, and immunological characterization of COVID-
19 was approved by the Regional Ethic Committee (106624, clinicaltrials.gov
NCT04381819). As the initial study population, forty consecutive patients in
the two hospitals between March 6 and April 14, with acute SARS-CoV-2
infection proven by positive real-time PCR test targeting the E-gene, were
eligible for inclusion (35). Due to logistical reasons including high numbers
of daily hospital admissions, inclusion of patients was random.
Reference population. Healthy blood donors served as reference populations
for the different complement activations assays, as described in detail below.
Data Collection. Using a modified version of the International Severe Acute
Respiratory and Emerging Infection Consortium/World Health Organization
Clinical Characterization Protocol, epidemiological, demographic, clinical,
laboratory, treatment, and outcome data were abstracted from electronic
medical records into deidentified case record forms on a REDCap database
(Research Electronic Data Capture, Vanderbilt University, hosted by University
of Oxford). All data were quality-checked by two physicians, and a third
researcher adjudicated any difference in interpretation between the two
physicians.
Laboratory Procedures. Blood samples were obtained at hospital admission
(within 48 h), at days 3 to 5, and days 7 to 10 (with one exceptionwhen sample
was acquired at day 12). Venous blood samples were collected with 4-mL
Vacutainer (BD Biosciences) with ethylenediaminetetraacetic acid (EDTA) as
anticoagulant. Samples were immediately stored on ice and processed within
30 min, and plasma was isolated by refrigerated centrifugation at 2,000 × g
for 20 min to obtain platelet-poor plasma and immediately stored at –80 °C.
Complement Analyses. All assays were conducted blinded to clinical infor-
mation. The complement activation products C3bBbP, C3bc, and the terminal
complement complex sC5b-9 were quantified using enzyme-linked immu-
nosorbent assays (ELISAs) based on monoclonal antibodies designed against
neoepitopes of the products, not reacting with the native component, and
performed as described in detail previously (36). The units of these three
well-established in-house assays are given according to an international
standard defined as complement activation units (CAU) per milliliter with
blood donors to define upper reference values of the normal population
(36). In detail, 20 females and 20 males aged 18 y to 65 y were analyzed for
C3BbBp, C3bc, and sC5b-9 complement activation products. There was no
statistical difference between females and males, and the groups were thus
combined to 40 individuals. The upper reference limit was set to the 95th
percentile, and values above these were regarded as positive. Calculations
were made both by absolute values as correlations (Spearman) or as positive
versus negative (χ2). The commercially available assays were used to measure
plasma C4d (SVAR Life Science), C5a, and MBL (Hycult Biotech). The refer-
ence values for C4d were given by the supplier, testing EDTA plasma from
healthy donors, and, for C5a and MBL, the reference range was based on
previously published data from us and others (32, 37).
Summary of the upper reference limits, with the units given above, were
for the five activation products: sC5b-9, <0.7; C5a, <2.0; C3bc, < 9.0;
C3BbBp, < 24; and C4d, <1,000. For MBL, which is not an activation product
but a recognition molecule, the limits are regarded as deficient <100, low in
range 100 to 500, and normal >500.
Antibody Analyses Using Flow Cytometric Bead Assay. A multiplexed bead-
based flow cytometric assay, referred to as microsphere affinity proteomics,
was adapted for detection of SARS-CoV-2 antibodies (38, 39). Thus amine-
functionalized polymer beads were color-coded with fluorescent dyes as de-
scribed earlier and reacted successively with amine-reactive biotin (sulfo-NHS-LC-
biotin, Proteochem) and neutravidin (Thermo Fisher). A DNA construct encoding
the receptor-binding domain of Spike-1 protein (RBD) from SARS-CoV-2 was
provided by Florian Krammer, and used to produce recombinant protein as
described in SI Appendix, Supplementary Method S1 (40). Bacterially expressed
full-length nucleocapsid protein from SARS-CoV-2 was purchased from Prospec
Bio. Viral proteins solubilized in phosphate-buffered saline (PBS) were bio-
tinylated chemically using a four to one molar ratio of sulfo-NHS-LC-biotin to
protein. Free biotin was removed with G50 sephadex spin columns. Biotinylated
proteins were bound to neutravidin-coupled microspheres with fluorescent
barcodes and cross-linked with the homobifunctional cross-linker BS3 (Pro-
teochem) for irreversible binding. Beads with Neutravidin only were used as
reference for background binding. Sera were diluted 1:1,000 in PBS containing
1% Tween 20 (PBT), 1% bovine serum albumin, 10 ug/mL d-biotin, and 10 ug/mL
Neutravidin (Thermo Fisher) and incubated with a mixture of antigen-coupled
and Neutravidin-only beads for 1 h at 22 °C under constant agitation. The beads
were washed twice in PBT, labeled with R-Phycoerythrin-conjugated goat-
anti-Human IgG-Fc or IgM-Fc (Jackson Immunoresearch) for 20 min, washed
again, and analyzed by flow cytometry (Attune Next, Thermo Fisher).
Specific binding was measured as the ratio of R-Phycoerythrin fluorescence
intensity of antigen-coupled beads and neutravidin-only beads. Samples
containing antibodies to both nucleocapsid protein and RBD were con-
sidered to be positive. A reference panel containing samples from 63 in-
dividuals with PCR-confirmed SARS-CoV-2 infection and 86 prepandemic
samples was used to set the cutoff. With a cutoff set to obtain a specificity
of 100%, the sensitivity was 84%. We also compared antibody concentra-
tion detected by flow cytometric analysis to antibodies detected by ELISA
(SI Appendix, Supplementary Method S1 and Figs. S4 and S5) and observed
good correlation (SI Appendix, Fig. S6).
Viral Load Analyses. RNA was extracted from clinical samples by MagNA Pure
96 system (Roche). SARS-CoV-2 RNA real-time RT-PCR was performed as
described by Corman et al. (35) using E-gene as target. PCR reactions were
run on an AriaDx PCR instrument (Agilent Technologies), and viral load was










































calculated using standard dilution series of purified RNA of SARS-CoV-2
strain Frankfurt1 (European Virus Archive Global). The sample quality was
analyzed by RNaseP real-time RT-PCR protocol described by Centers for
Disease Control and Prevention (https://www.cdc.gov/coronavirus/2019-
ncov/lab/rt-pcr-panel-primer-probes.html; Division of Viral Diseases, Na-
tional Center for Immunization and Respiratory Diseases), and found valid
for all specimens. In cases of PCR inhibition, samples were tested in 1:10
dilutions.
Outcomes, Calculations, and Statistical Analyses. In patients missing arterial
oxygen tension (PO2), PO2 was approximated from peripheral O2 satu-
ration (41). Likewise, fraction of inspired oxygen (FiO2) in nonmechani-
cally ventilated patients was approximated from supplementation of
oxygen (42). Respiratory failure was defined according to the pO2/FiO2
ratio limits described in the ARDS Berlin definition regardless of venti-
latory support (43). Thus, respiratory failure was present when PO2/FiO2
ratio was ≤40 kPa. SOFA score was calculated at each time point, while
quick SOFA (qSOFA) and National Early Warning Score (NEWS) were
calculated at admission day only, due to lack of information on respira-
tory rate and confusion status at later time points (44). The eGFR was
calculated according to the Modification of Diet in Renal Disease
formula (45).
Outcome variables for the clinical course of COVID-19 patients were de-
termined before statistical analyses and consisted of dichotomized respira-
tory failure (yes/no) daily or over the whole hospital course, respiratory
failure stage (according to PO2/FiO2 values used in ARDS classification as
none, mild, moderate, and severe), need for oxygen therapy (yes/no), daily
FiO2, daily PO2, and daily PO2/FiO2 ratio.
Complement activation products were nonnormally distributed and thus
transformed using the natural logarithm for comparisons between groups
with the linear mixed model analysis with subject as random effect and time
and respiratory failure as fixed effects (also as interaction). Further, Man-
n−Whitney U, Χ2 test, Spearman´s rank test, and Kruskal−Wallis test were
used, as appropriate, for comparison of groups. Linear, logistic, and ordinal
regression models were used to assess associations between complement
components as predictors of characteristics and stages of respiratory failure
(syntax presented in SI Appendix, Table S4). More specifically, regression
analyses were used to determine risk factors for development of respiratory
failure and the composite endpoint of admission to intensive care unit and/
or death. The following variables were investigated as independent risk
factors: complement activation products, and clinical laboratory markers
white blood cell count, ferritin, CRP, d-dimer, and thrombocyte count.
Analyses were not corrected for confounders, as sample size was small.
Missing values in biobank samples were frequent; thus, number is reported
for every analysis. Statistical analyses were performed using IBM SPSS Sta-
tistics for Macintosh, Version 26.0 (IBM Corp.) and GraphPad Prism version 8
(GraphPad Software).
Data Availability. Anonymized quantitative data in an SPSS database have
been deposited in Norwegian Centre for Research Data and is freely available
upon registration for noncommercial use (https://doi.org/10.18712/NSD-
NSD2880-V2) (46).
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